Assessment of Patient Experiences with Respimat^® in Everyday Clinical Practice.

ABSTRACT:

Introduction

Chronic obstructive pulmonary disease (COPD) is a progressive disease requiring maintenance therapy. According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy report, bronchodilation with long-acting muscarinic antagonists (LAMAs) and long-acting β₂-agonists (LABAs), administered via inhalers, is currently the mainstay of COPD treatment. Combined LAMA/LABA therapies have been shown to improve patient health status, lung function and breathlessness. Here, we wanted to report patient satisfaction with the Respimat^® Soft Mist™ inhaler (SMI).

Methods

This was a pooled analysis of SPIRIT^® (NCT02675517) and OTIVACTO^® (NCT02719639), two open-label, single-arm, non-interventional studies of physic

SUBMITTER: Taube C 

PROVIDER: S-EPMC7671953 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature